Treatment Program for Anemia in AIDS Patients

Not Applicable

Completed

• Conditions: HIV Infections; Cytopenias

• Registration Number: NCT00002022
• Lead Sponsor: R W Johnson Pharmaceutical Research Institute

Brief Summary

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 1991-02
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

R W Johnson Pharmaceutical Research Institute; 🇺🇸 Raritan, New Jersey, United States